8 reports

(USA) ##.

  • Cancer
  • Stem Cell Transplant
  • United States
  • World
  • Market Shares

The molecules developed by companies in Phase III, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Hospital
  • Stem Cell Transplant
  • Therapy
  • United States
  • Product Initiative

The molecules developed by companies in Phase III and Preclinical stages are ## and ## respectively.

  • General Medicine And Specialty Medicine
  • Stem Cell Transplant
  • Therapy
  • United States
  • Product Initiative
  • JUN 23, 2017: BELLICUM ANNOUNCES CLINICAL DATA ON BPX-501 AT PRESIDENTIAL SYMPOSIUM OF THE 22ND CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION

About BPX-## BPX-## is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum' s CaspaCIDe® safety switch.

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Stem Cell Transplant
  • World
  • Product Initiative

Bellicum' s lead pipeline candidate includes BPX-##, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas, and genetic blood diseases.

  • Blood Disease
  • Cell Therapy
  • Stem Cell Transplant
  • Transplantation
  • Athersys, Inc.

## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## Source

  • Blood Disease
  • General Medicine And Specialty Medicine
  • Stem Cell Transplant
  • World
  • Product Initiative

Majority of JMML patients are observed to contain genetic abnormalities.

  • Cancer
  • Leukemia
  • Stem Cell Transplant
  • United States
  • Product Initiative

HEMATOPOIETIC STEM CELL TRANSPLANTATION - PIPELINE BY NOVARTIS AG, H## 2016 P##D Bioscience (P##D) is a pharmaceutical company that develops drugs for genetic orphan diseases.

  • Cell Therapy
  • General Medicine And Specialty Medicine
  • Stem Cell Transplant
  • Transplantation
  • Athersys, Inc.